

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
January 31, 2012

Ultralife Corporation
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-20852
(Commission File Number)

16-1387013
(IRS Employer
Identification No.)

2000 Technology Parkway, Newark, New York
(Address of principal executive offices)

14513
(Zip Code)

(315) 332-7100
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

Ultralife Corporation (NASDAQ: ULBI) has received a contract to supply 2,319 of its A-320 amplifier systems to a major international defense contractor. Due to the sensitive nature of this contract, the company is not able to disclose the total value of the contract. Deliveries will commence in the first half of 2012.

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed to be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Item 9.01. Financial Statements and Exhibits.

- (a) Exhibits.
99.1 Press Release dated January 31, 2012

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Ultralife Corporation

Date: January 31, 2012

By: /s/ PETER F. COMERFORD
Peter F. Comerford
Vice President of Administration
General Counsel and Secretary

INDEX TO EXHIBITS

- (99) Additional Exhibits
99.1 Press Release dated January 31, 2012

Ultralife Corporation Receives International Communications Systems Contract

NEWARK, N.Y., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Ultralife Corporation (Nasdaq:ULBI) has received a contract to supply 2,319 of its A-320 amplifier systems to a major international defense contractor. Due to the sensitive nature of this contract, the company is not able to disclose the total value of the contract. Deliveries will commence in the first half of 2012.

"This contract demonstrates progress towards the strategic expansion of our core U.S. government and defense business into a broader global presence with international allies," said Michael D. Popielec, Ultralife's president and chief executive officer. "As we continue to develop new products across our business, our amplifier platform provides a technically advanced building block for the increasingly complex, secure communications systems required for soldier modernization. In this case, our amplifiers have been selected as a critical component of the secure communications backbone for a multi-phased, strategic command, control, and communications modernization program."

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from portable power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the company's business segments include: Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorp.com.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: uncertain global economic conditions, increased competitive environment and pricing pressures, disruptions related to restructuring actions and delays. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

CONTACT: Ultralife Corporation
Philip Fain
(315) 332-7100
pfain@ulbi.com

Investor Relations Contact:
Lippert/Heilshorn & Associates
Jody Burfening
(212) 838-3777
jburfening@lhai.com